Core Viewpoint - Duori Pharmaceutical is undergoing a potential change in control, which may lead to a shift in its major shareholder and actual controller, with stock suspension expected for no more than two trading days [1] Group 1: Company Overview - Duori Pharmaceutical primarily engages in the research, production, and sales of chemical drug formulations, intermediates, and active pharmaceutical ingredients [1] - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in September 2021 [1] Group 2: Financial Performance - The company has experienced a continuous decline in net profit from 2021 to 2024, with figures of 68.51 million, 20.50 million, 18.85 million, and a loss of 62.67 million respectively, reflecting year-on-year decreases of 25.53%, 70.07%, 8.05%, and 432.44% [1][2] - Revenue has also decreased for three consecutive years, with 2022 to 2024 revenues of 401 million, 334 million, and 241 million, showing year-on-year declines of 24.28%, 16.64%, and 28.02% [2] - In the first half of 2025, revenue continued to decline to 107 million, a year-on-year decrease of 29.13%, with a net profit loss of 42.50 million compared to a loss of 3.28 million in the same period last year [2] Group 3: Profitability and Financial Ratios - The company's gross margin has sharply declined from 88.61% in 2021 to 42.42% in 2024, plummeting to 4.07% in the first half of 2025 [2] - The asset-liability ratio increased significantly from 23.37% at the end of 2023 to 50.91% at the end of 2024, further rising to 52.01% by mid-2025 [2]
连亏一年半！多瑞医药上市4年后筹划控制权变更